Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tashkin, Donald P., Elashoff, Robert, Clements, Philip J., Roth, Michael D., Furst, Daniel E., Silver, Richard M., Goldin, Jonathan, Arriola, Edgar, Strange, Charlie, Bolster, Marcy B., Seibold, James R., Riley, David J., Hsu, Vivien M., Varga, John, Schraufnagel, Dean, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fred, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark, Khanna, Dinesh, Li, Ning, Li, Gang
Formato: Artigo
Idioma:Inglês
Publicado: American Thoracic Society 2007
Assuntos:
E. Interstitial Lung Disease
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2078679/
https://ncbi.nlm.nih.gov/pubmed/17717203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.200702-326OC
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares